...Interleukin-9IL-12 – Interleukin-12KIR3DL2 (CD158K) – Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 MicroRNA-155 (miR-155)PD1...

...extend its cash runway into 2Q20. Targets: miR-29 - MicroRNA-29; miR-92a - MicroRNA-92a; miR-155 - MicroRNA-155; BioCentury...

...inhibitory factor (MIF) Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1) MAP kinase 12 (MAPK12) (ERK-3) (p38 gamma) MicroRNA-155 (miR-155) NLR...

...testing identified genes regulated by HHV-6A, including microRNA-155 (miR-155), which affects the brain's neuronal fraction. miR-155...
...been shown to regulate T cell response to AD. In a mouse model of amyloidosis, miR-155...
...miR-155, a potential mediator of neuronal loss. Elizabeth S. Eaton Icahn School of Medicine at Mount Sinai MicroRNA-155 (miR-155...

...or 900 mg doses of subcutaneous or IV MRG-106, a synthetic oligonucleotide that inhibits microRNA-155 (miR-155...
...achieves broad distribution, microRNAs with important functions in non-diseased tissue will not be suitable targets. miR-155...
...the U.S. and Japan. miRagen’s fourth program is MRG-107 . Like MRG-106, it also targets miR-155...

...for a systemic anti-microRNA therapy in oncology. MRG-106 is a synthetic microRNA antagonist of microRNA-155 (miR-155...
...Boulder, Colo. Product: MRG-106 Business: Cancer Molecular target: MicroRNA-155 (miR-155) Description: Synthetic microRNA antagonist of miR-155...
...Status: Interim Phase I data Milestone: Additional Phase I data (12/2017) Elizabeth S. Eaton MRG-106 Miragen Therapeutics Inc. MicroRNA-155 (miR-155) European...

...600 or 900 mg doses of subcutaneous or IV MRG-106, a synthetic microRNA antagonist of microRNA-155...
...the therapy next year. miRagen gained $0.21 to $9.42 on Friday. Elizabeth S. Eaton MRG-106 Miragen Therapeutics Inc. MicroRNA-155 (miR-155...

...27% and Signal's shareholders will own 4%. miRagen’s MRG-106 , a synthetic miRNA antagonist of miR-155...
...Inc. (NASDAQ:SGNL), New York, N.Y. Business: Cancer, Cardiovascular, Neurology Jaime De Leon MRG-106 MRG-201 miRagen Therapeutics Inc. Signal Genetics Inc. MicroRNA-155 (miR-155) MicroRNA-29b...

...will own 27% and Signal's shareholders 4%. miRagen’s MRG-106 , a synthetic miRNA antagonist of miR-155...
...to $0.50 on Tuesday. Jaime De Leon MRG-106 MRG-201 Myeloma Prognostic Risk Signature (MyPRS) test miRagen Therapeutics Inc. Signal Genetics Inc. MicroRNA-155 (miR-155) MicroRNA-29...

...Infectious disease INDICATION: Leishmaniasis Cell culture and mouse studies suggest inhibiting the miR-155 /AKT signaling pathway...
...within disease lesions compared with normal miR-155 expression. Next steps could include identifying and testing miR-155...
...lateral sclerosis (ALS). TARGET/MARKER/PATHWAY: Protein kinase B (AKT; AKT1 ; PKB ; PKBA ); microRNA-155 (miR-155...